Search
Displaying 641–650 of 705 for “retinitis clinical trial”
-
FDA Approves New Wet AMD Treatment that can be Administered Every Three Months
Research NewsBeovu from Novartis reduces treatment burden for wet AMD patients
-
Beacon Stories
Shawn was diagnosed with Usher syndrome at a young age. Shawn now stays involved with the blind community and participates in his local blind hockey league. In his own words, he shares his journey at the Toyota-USA Hockey Disabled Hockey Festival.
-
How Davida Regained Her Speed with Guide Dog Chubb
Beacon StoriesIn honor of National Guide Dog Month this September, Davida is sharing her experience with the Guide Dog Foundation for the Blind and how she found a perfect match in her new guide dog, Chubb.
-
Beacon Stories
13 year old Kailey Reichardt’s personal essay about her little sister Ashlyn, who was diagnosed with Leber congenital amarosis (LCA) at a young age. Kailey is a Beacon for other siblings impacted and going through similar situations.
-
Sustained Suppression of VEGF: Looking Forward and Looking Back
Research NewsThe results of the LADDER trial demonstrate a major step forward but introduce many questions.
-
Join a growing movement of changemakers who are transforming passion into purpose and turning everyday moments into life-changing impact. When you fundraise for the Foundation Fighting Blindness, you accelerate the science that saves sight—for millions.
-
National Science Update - May 29, 2019
A deep dive into the research and clinical trial results that impact the inherited retinal disease community.
-
Tackling the Next Gene Therapy Challenge: Autosomal Dominant Diseases
Foundation NewsA discussion of strategies concerning the development of autosomal dominant disease therapies at the Translational Research Acceleration Program (TRAP) in November 2013.
-
Dr. Don Zack Honored for Research Contributions by ARVO and the Foundation Fighting Blindness
Research NewsDr. Zack is a member of the Foundation’s Scientific Advisory Board and chairs its Cellular Molecular Mechanisms of Disease study section.
-
ARVO 2019: Emerging Eloxx Molecules Show Promising Results in Usher Models
Research NewsEloxx Pharmaceuticals is developing small molecules that permit read-through of point mutations that cause Usher syndrome 1F and 2A.
